» Articles » PMID: 26966724

Korean Clinical Practice Guideline for Benign Prostatic Hyperplasia

Overview
Specialty Urology
Date 2016 Mar 12
PMID 26966724
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

In 2014, the Korean Urological Association organized the Benign Prostatic Hyperplasia Guideline Developing Committee composed of experts in the field of benign prostatic hyperplasia (BPH) with the participation of the Korean Academy of Family Medicine and the Korean Continence Society to develop a Korean clinical practice guideline for BPH. The purpose of this clinical practice guideline is to provide current and comprehensive recommendations for the evaluation and treatment of BPH. The committee developed the guideline mainly by adapting existing guidelines and partially by using the de novo method. A comprehensive literature review was carried out primarily from 2009 to 2013 by using medical search engines including data from Korea. Based on the published evidence, recommendations were synthesized, and the level of evidence of the recommendations was determined by using methods adapted from the 2011 Oxford Centre for Evidence-Based Medicine. Meta-analysis was done for one key question and four recommendations. A draft guideline was reviewed by expert peer reviewers and discussed at an expert consensus meeting until final agreement was achieved. This evidence-based guideline for BPH provides recommendations to primary practitioners and urologists for the diagnosis and treatment of BPH in men older than 40 years.

Citing Articles

for the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Enlargement: An Updated Cochrane Review.

Franco J, Trivisonno L, Sgarbossa N, Alvez G, Fieiras C, Escobar Liquitay C World J Mens Health. 2024; 42(3):518-530.

PMID: 38164033 PMC: 11216968. DOI: 10.5534/wjmh.230222.


Feasibility study on a new enhanced device for patients with intermittent catheterization (LUJA).

Calabro G, DAmbrosio F, Orsini F, Pappalardo C, Scardigno A, Rumi F J Prev Med Hyg. 2023; 64(3 Suppl 1):E1-E89.

PMID: 38125911 PMC: 10730013. DOI: 10.15167/2421-4248/jpmh2023.64.3s1.


Changes of resistance indices after medication in benign prostatic hyperplasia: a prospective study.

Park D, Kwon S, Seo Y, Byun H, Lee K Prostate Int. 2023; 11(3):139-144.

PMID: 37745908 PMC: 10513904. DOI: 10.1016/j.prnil.2023.02.001.


Efficacy and safety of low power holmium laser enucleation of the prostate: A prospective short- and medium-term single-blind randomized trial.

Suh J, Choo M, Oh S Investig Clin Urol. 2023; 64(5):480-488.

PMID: 37668204 PMC: 10482670. DOI: 10.4111/icu.20230017.


Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement.

Franco J, Trivisonno L, Sgarbossa N, Alvez G, Fieiras C, Escobar Liquitay C Cochrane Database Syst Rev. 2023; 6:CD001423.

PMID: 37345871 PMC: 10286776. DOI: 10.1002/14651858.CD001423.pub4.


References
1.
Roehrborn C, Boyle P, BERGNER D, Gray T, Gittelman M, Shown T . Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology. 1999; 54(4):662-9. DOI: 10.1016/s0090-4295(99)00232-0. View

2.
Jones C, Hill J, Chapple C . Management of lower urinary tract symptoms in men: summary of NICE guidance. BMJ. 2010; 340:c2354. DOI: 10.1136/bmj.c2354. View

3.
Tricoci P, Allen J, Kramer J, Califf R, Smith Jr S . Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA. 2009; 301(8):831-41. DOI: 10.1001/jama.2009.205. View

4.
Roehrborn C, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I . The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2009; 57(1):123-31. DOI: 10.1016/j.eururo.2009.09.035. View

5.
Roehrborn C, Siami P, Barkin J, Damiao R, Becher E, Minana B . The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the.... Eur Urol. 2008; 55(2):461-71. DOI: 10.1016/j.eururo.2008.10.037. View